Per Stål

14.4k citations

135 papers · 7.7k indexed · 4 hit papers · h-index 35

Impact in

Hepatology top 0.1%
- Liver Disease and Transplantation
- Liver Diseases and Immunity
- Hepatocellular Carcinoma Treatment and Prognosis
- Hepatitis C virus research
Epidemiology top 0.2%
- Liver Disease Diagnosis and Treatment

Papers in ⓘ

Hepatology 65
- Hepatocellular Carcinoma Treatment and Prognosis 28
- Liver Disease and Transplantation 28
- Liver Diseases and Immunity 17
- Hepatitis C virus research 12
Hematology 23
- Iron Metabolism and Disorders 23

Co-authors: Rolf Hultcrantz (37 shared papers)Hannes Hagström (39 shared papers)Mattias Ekstedt (18 shared papers)Stergios Kechagias (17 shared papers)Patrik Nasr (15 shared papers)Mats Fredrikson (2 shared papers)Ulf Hammar (4 shared papers)Johan Askling (6 shared papers)
Journals: Scandinavian Journal of Gastroenterology (17 papers)Journal of Hepatology (15 papers)Liver International (13 papers)Hepatology (8 papers)Journal of Clinical Oncology (5 papers)
Partner nations: Sweden United States Italy

In The Last Decade

Per Stål

130 papers receiving 7.5k citations

Hit Papers

align trajectories log scale

Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD 2017 · 732 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2017 Journal of Hepatology
2017 Hepatology
2014 Hepatology
2009 Hepatology

Peers

Countries citing papers authored by Per Stål

Since Specialization

Citations

This map shows the geographic impact of Per Stål's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Per Stål with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Per Stål more than expected).

Fields of papers citing papers by Per Stål

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Per Stål. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Per Stål. The network helps show where Per Stål may publish in the future.

Co-authors

The 25 scholars most cited alongside Per Stål, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Per Stål Line = papers co-authored together Per Stål links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 135 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up Hepatology ·Mattias Ekstedt, Hannes Hagström, Patrik Nasr, Mats Fredrikson, Per Stål, Stergios Kechagias, Rolf Hultcrantz Hit paper breakdown →	2014	1662
2	Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis Hepatology ·Parambir S. Dulai, Siddharth Singh, Janki Patel, Meera Soni, Larry J. Prokop, Zobair M. Younossi, Giada Sebastiani, Mattias Ekstedt, Hannes Hagström, Patrik Nasr, Per Stål, Vincent Wai‐Sun Wong, Stergios Kechagias, Rolf Hultcrantz, Rohit Loomba Hit paper breakdown →	2017	1342
3	Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD Journal of Hepatology ·Hannes Hagström, Patrik Nasr, Mattias Ekstedt, Ulf Hammar, Per Stål, Rolf Hultcrantz, Stergios Kechagias Hit paper breakdown →	2017	732
4	Decreased Survival of Subjects With Elevated Liver Function Tests During A 28-Year Follow-Up Hepatology ·Cecilia Söderberg, Per Stål, Johan Askling, Hans Glaumann, Greger Lindberg, Joel Marmur, Rolf Hultcrantz Hit paper breakdown →	2009	604
5	Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long‐term follow‐up study Hepatology Communications ·Hannes Hagström, Patrik Nasr, Mattias Ekstedt, Ulf Hammar, Per Stål, Rolf Hultcrantz, Stergios Kechagias	2017	219
6	Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives Gastroenterology ·Maria Elmberg, Rolf Hultcrantz, Anders Ekbom, Lena Brandt, Sigvard Olsson, Rolf Olsson, Stefan Lindgren, Lars Lööf, Per Stål, Sven Wallerstedt, Sven Almér, Hanna Sandberg–Gertzén, Johan Askling	2003	198
7	A Risk for Hepatocellular Carcinoma Persists Long-term After Sustained Virologic Response in Patients With Hepatitis C–Associated Liver Cirrhosis Clinical Infectious Diseases ·Soo Aleman, Nogol Rahbin, Ola Weiland, Lóa Davíðsdóttir, Magnus Hedenstierna, Nina F. Rose, Hans Verbaan, Per Stål, Tony Carlsson, Hans Norrgren, Anders Ekbom, Fredrik Granath, Rolf Hultcrantz	2013	176
8	Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet – a randomised controlled trial JHEP Reports ·Magnus Holmer, Catarina Lindqvist, Sven Petersson, John Moshtaghi‐Svensson, Veronika Tillander, Torkel B. Brismar, Hannes Hagström, Per Stål	2021	146
9	Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance World Journal of Gastroenterology ·Per Stål	2015	120
10	Accuracy of Noninvasive Scoring Systems in Assessing Risk of Death and Liver-Related Endpoints in Patients With Nonalcoholic Fatty Liver Disease Clinical Gastroenterology and Hepatology ·Hannes Hagström, Patrik Nasr, Mattias Ekstedt, Per Stål, Rolf Hultcrantz, Stergios Kechagias	2018	85
11	HFE mutations in patients with hereditary haemochromatosis in Sweden Journal of Internal Medicine ·Elsa M. Cardoso, Per Stål, Hagen, José Manuel Cabeda, Esin, Maria de Sousa, Hultcrantz	1998	80
12	Low to moderate lifetime alcohol consumption is associated with less advanced stages of fibrosis in non-alcoholic fatty liver disease Scandinavian Journal of Gastroenterology ·Hannes Hagström, Patrik Nasr, Mattias Ekstedt, Stergios Kechagias, Kristina Önnerhag, Emma Nilsson, Fredrik Rorsman, Reza Sheikhi, Hanns–Ulrich Marschall, Rolf Hultcrantz, Per Stål	2016	75
13	Cardiovascular risk factors in non‐alcoholic fatty liver disease Liver International ·Hannes Hagström, Patrik Nasr, Mattias Ekstedt, Ulf Hammar, Per Stål, Johan Askling, Rolf Hultcrantz, Stergios Kechagias	2018	75
14	Erythropoietic protoporphyria in Sweden: demographic, clinical, biochemical and genetic characteristics Journal of Internal Medicine ·Staffan Wåhlin, Ylva Flodérus, Per Stål, Pauline Harper	2010	70
15	Characteristics and outcome of hepatocellular carcinoma in patients with NAFLD without cirrhosis Liver International ·Bonnie Bengtsson, Per Stål, Staffan Wåhlin, Niklas K. Björkström, Hannes Hagström	2019	66
16	Elevated serum ferritin is associated with increased mortality in non‐alcoholic fatty liver disease after 16 years of follow‐up Liver International ·Hannes Hagström, Patrik Nasr, Matteo Bottai, Mattias Ekstedt, Stergios Kechagias, Rolf Hultcrantz, Per Stål	2016	63
17	Iron increases ethanol toxicity in rat liver Journal of Hepatology ·Per Stål, Rolf Hultcrantz	1993	61
18	Overweight in late adolescence predicts development of severe liver disease later in life: A 39years follow-up study Journal of Hepatology ·Hannes Hagström, Per Stål, Rolf Hultcrantz, Tomas Hemmingsson, Anna Andréasson	2016	55
19	Retained NK Cell Phenotype and Functionality in Non-alcoholic Fatty Liver Disease Frontiers in Immunology ·Natalie Stiglund, Kristina Strand, Martin Cornillet, Per Stål, Anders Thorell, Christine L. Zimmer, Erik Näslund, Silja Karlgren, Henrik Nilsson, Gunnar Mellgren, Johan Fernø, Hannes Hagström, Niklas K. Björkström	2019	54
20	Biliary dysplasia, cell proliferation and nuclear  DNA‐fragmentation in primary sclerosing cholangitis with and without cholangiocarcinoma Journal of Internal Medicine ·Annika Bergquist, Hans Glaumann, Per Stål, Gangshi Wang, Ulrika Broomé	2001	53

About Per Stål

Per Stål is a scholar working on Hepatology, Hematology, Epidemiology, Genetics and Pathology and Forensic Medicine, having authored 135 papers that have together received 7.7k indexed citations. Recurring topics across this work include Liver Disease Diagnosis and Treatment (65 papers), Hepatocellular Carcinoma Treatment and Prognosis (28 papers), Liver Disease and Transplantation (28 papers), Iron Metabolism and Disorders (23 papers), Liver Diseases and Immunity (17 papers), Alcohol Consumption and Health Effects (14 papers), Hepatitis C virus research (12 papers) and Trace Elements in Health (12 papers). The work is most often cited by research in Hepatology (3.6k citations), Epidemiology (6.0k citations), Endocrinology, Diabetes and Metabolism (2.2k citations), Pathology and Forensic Medicine (1.0k citations) and Hematology (449 citations). Per Stål has collaborated with scholars based in Sweden, United States and Italy. Frequent co-authors include Rolf Hultcrantz, Hannes Hagström, Mattias Ekstedt, Stergios Kechagias, Patrik Nasr, Mats Fredrikson, Ulf Hammar, Johan Askling, Hans Glaumann and Greger Lindberg. Their work appears in journals such as Scandinavian Journal of Gastroenterology, Journal of Hepatology, Liver International, Hepatology and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact